Surpassing Standards in Diabetes Care – Novel Dual Incretin Receptor Agonists

SUPPPORT STATEMENT
Supported by an independent educational grant from Lilly

08:15 – 08:25

Better Metabolic Health with Incretin-based Therapies – Achievements and Ambitions

Michael Nauck  (GER)

 

08:25 – 08:40

The Power of novel dual GIP/GLP-1 Receptor Agonists 

Tina Vilsbøll (DNK)

08:40 – 09:00

The Clinical Evidence for GIP/GLP-1 Receptor Agonists – The Emerging Profile in Context

Melanie Davies (UK)

09:00 – 09:15

Panel Discussion and Q & A

All Faculty

09:15

Adjourn